Published in

Wiley, European Journal of Organic Chemistry, 40(26), 2023

DOI: 10.1002/ejoc.202300644

Links

Tools

Export citation

Search in Google Scholar

Tumor Carbohydrate Associated Antigen Analogs as Potential Binders for Siglec‐7

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractWe investigated two recently synthesized and characterized sialyl derivatives, bearing the Neu5Ac‐α‐(2‐6)‐Gal epitope, as promising binders for Siglec‐7, an inhibitory Siglec mainly found on natural killer cells. A variety of sialoglycan structures can be recognized by Siglec‐7 with implications in the modulation of immune responses. Notably, overexpression of sialylated glycans recognized by Siglec‐7 can be associated with the progression of several tumors, including melanoma and renal cell carcinoma. NOE‐based NMR techniques, including Saturation Transfer Difference and transferred‐NOESY NMR, together with molecular docking and dynamic simulations were combined to shed light on the molecular basis of Siglec‐7 recognition of two conformationally constrained Sialyl‐Tn antigen analogs. We, therefore, identify the ligands epitope mapping and their conformational features and propose 3D models accurately describing the protein‐ligand complexes. We found that the binding site of Siglec‐7 can accommodate both synthetic analogs, with the sialic acid mainly involved in the interaction. Moreover, the flexibility of Siglec‐7 loops allows a preferred accommodation of the more rigid compound bearing a biphenyl moiety at position 9 of the sialic acid that contributed to the interaction to a large extent. Our findings provided insights for developing potential novel high affinity ligands for Siglec‐7 to hinder tumor evasion.